LONDON, March 4, 2026 /PRNewswire/ -- The "Structural Heart Devices Market – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032" report has been added to the Credence Research Inc. offering.

The global Structural Heart Devices Market was valued at USD 5.21 billion in 2018, reached USD 6.68 billion in 2024, and is anticipated to reach USD 12.93 billion by 2032, registering a CAGR of 8.65% during the forecast period. The market's growth reflects rising structural heart disease prevalence, expanding clinical indications for transcatheter therapies, and strong physician and patient preference for minimally invasive procedures that improve recovery outcomes.

Key Takeaways:

• Rising prevalence of valvular heart disease and congenital heart defects is increasing demand for advanced structural heart interventions across aging populations.
• Minimally invasive transcatheter procedures especially TAVR continue to accelerate adoption due to faster recovery, lower procedural risk, and broader eligibility across risk categories.
• Ongoing innovation in transcatheter heart valves, delivery systems, and closure devices, supported by integrated imaging and navigation technologies, is improving procedural precision and outcomes.
• North America leads with ~40.8% share in 2024, supported by advanced cardiac care infrastructure and higher procedure volumes, while Asia Pacific is the fastest-growing region with ~10.0% CAGR driven by expanding healthcare investment and access.

Scope & Segmentation – Structural Heart Devices Market

The report provides a comprehensive analysis of the global Structural Heart Devices Market, covering revenue forecasts from 2024 to 2032. It evaluates market drivers, trends, challenges, competitive landscape, and regional dynamics across transcatheter and surgical device categories. The study assesses innovation in transcatheter valve replacement and repair, expanding regulatory approvals, clinical evidence development, and the role of advanced imaging and navigation technologies in improving procedural safety and effectiveness.

The structural heart devices market is segmented based on product, procedure, end-use, and geography.

• By Product, the market includes Heart Valve Devices (Surgical Heart Valves, Transcatheter Heart Valves), Annuloplasty Rings, Occluders & Delivery Systems, and Other Products.
• By Procedure, the market includes Replacement Procedures (SAVR, TAVR, TMVR, Others) and Repair Procedures (LAAC, TMVr, TTVr, Valvuloplasty, Others).
• By End-use, the market includes Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Labs, and Other End Use.
• By Geography, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with country-level coverage including the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, China, Japan, India, South Korea, Southeast Asia, Brazil, Argentina, GCC countries, and South Africa.

Request your sample report today & start making informed decisions powered by Credence Research Inc.! - https://www.credenceresearch.com/report/structural-heart-devices-market

Why This Report Matters

• This report delivers a detailed view of a high-impact cardiovascular devices segment, with the market projected to nearly double by 2032, supported by strong transcatheter procedure momentum.
• It helps decision-makers evaluate how TAVR expansion, transcatheter mitral/tricuspid innovation, and closure device adoption are reshaping structural heart care pathways.
• The study provides regional insights across major markets and emerging economies, helping manufacturers and stakeholders prioritize investments, partnerships, and expansion strategies.
• For CXOs, investors, hospitals, and device innovators, this report offers actionable intelligence on competitive positioning, procedure trends, regulatory dynamics, and growth opportunities.

Market Overview:

• Industry Landscape and Value Chain Assessment
• Supply-Side Evaluation
• Demand-Side Evaluation
• Stakeholder Mapping
• Porter's Five Forces Review
• PESTLE Environment Assessment
• Market Forecast and Future Direction
• Short-Term Forecast (0–2 Years)
• Mid-Term Forecast (3–5 Years)
• Long-Term Forecast (5–10 Years)
• Market Entry and Expansion Strategy

Market Insights:

• Customer and End-User Analysis
• Customer Experience Comparison
• Growth Opportunity Assessment
• Channel and Distribution Review
• Pricing Movement Analysis
• Regulatory and Compliance Review
• Sustainability and ESG Assessment
• Risk and Disruption Analysis
• Investment Return and Cost Evaluation

Key Attributes

Regional Growth Reflects Procedure Adoption and Healthcare Capacity

• North America holds the largest share of the structural heart devices market, accounting for approximately 40.8% of the global market in 2024. The regional market size reached USD 2.73 billion in 2024 (up from USD 2.15 billion in 2018) and is projected to reach USD 5.30 billion by 2032, expanding at a CAGR of 8.7%. Advanced hospital infrastructure, robust adoption of transcatheter therapies, and higher procedure volumes support regional dominance.
• Europe follows with approximately 24.6% share in 2024, rising from USD 1.33 billion in 2018 to USD 1.64 billion in 2024, and is projected to reach USD 2.97 billion by 2032 at a CAGR of 7.7%. Strong cardiac centers, supportive reimbursement structures, and rising valvular disease prevalence contribute to steady growth.
• Asia Pacific is the fastest-growing region with ~10.0% CAGR and approximately 21.9% share in 2024. The market expanded from USD 1.09 billion in 2018 to USD 1.47 billion in 2024 and is expected to reach USD 3.15 billion by 2032, driven by expanding access, growing healthcare investment, and increasing adoption of minimally invasive procedures in major countries including China, Japan, and India.

Market Challenges Include High Costs, Regulatory Complexity, and Procedural Risk

Despite strong growth prospects, the market faces constraints from the high cost of devices and procedures, particularly transcatheter interventions that require expensive implants, specialized equipment, and skilled operators. Cost sensitivity and reimbursement limitations may restrict adoption in developing markets.

The market also faces stringent and time-intensive regulatory pathways, requiring robust clinical evidence, long trial cycles, and significant R&D investment. Approval delays can slow market entry and limit near-term expansion.

In addition, procedural and device-related complications including leakage, incorrect placement, and device malfunction remain concerns. Continued design improvements and standardized operator training are essential to expand adoption and sustain long-term growth.

Future Outlook

The Structural Heart Devices Market is poised for sustained growth through 2032, supported by the continued expansion of transcatheter procedures, broader clinical indications, and rapid technology innovation in valves, closure devices, and delivery systems.

Integration of imaging and navigation tools will continue improving accuracy and outcomes, while emerging markets will play a larger role as healthcare systems expand access to advanced cardiac interventions. As clinical adoption spreads beyond high-risk cohorts, structural heart therapies will remain central to the evolution of minimally invasive cardiovascular care.

Competitive Landscape

The structural heart devices market remains highly competitive, with leading companies focusing on product innovation, strategic partnerships, acquisitions, and geographic expansion. Major players including Abbott, Medtronic, Boston Scientific, Edwards Lifesciences, and LivaNova continue to invest in transcatheter platforms and expanded indications, while other companies strengthen niche capabilities and regional penetration across fast-growing markets.

Key Player Analysis

• Abbott;
• AtriCure;
• BIOMERICS;
• Boston Scientific;
• BRAILE;
• CryoLife;
• Edwards;
• JENAVALVE;
• LEPU MEDICAL;
• LivaNova;
• Medtronic;
• NUMED

Recent Industry Developments

• In July 2024, Edwards Lifesciences announced agreements to acquire JenaValve Technology (transcatheter treatment of aortic regurgitation) and to acquire Endotronix (heart-failure management solutions), positioning both as expansions of its structural heart portfolio.
• In August 2024, Edwards Lifesciences acquired JC Medical from Genesis MedTech, adding JC Medical's transcatheter aortic valve replacement technology aimed at native aortic regurgitation, and also made an additional equity investment of $25 million.

Download Sample - https://www.credenceresearch.com/report/structural-heart-devices-market 

Related Reports –

Congestive Heart Failure Treatment Devices Market https://www.credenceresearch.com/report/congestive-heart-failure-treatment-devices-market

Prosthetic Heart Valves Market https://www.credenceresearch.com/report/prosthetic-heart-valves-market

Transcatheter Heart Valve Replacement Market https://www.credenceresearch.com/report/transcatheter-heart-valve-replacement-market

Structural Heart Devices Market https://www.credenceresearch.com/report/structural-heart-devices-market

Cardiac Surgery and Heart Valve Devices Market https://www.credenceresearch.com/report/cardiac-surgery-and-heart-valve-devices-market

At-Home Heart Health Testing Market https://www.credenceresearch.com/report/at-home-heart-health-testing-market

Flea Tick and Heartworm Products Market https://www.credenceresearch.com/report/flea-tick-and-heartworm-products-market

Heart Valve Devices Market https://www.credenceresearch.com/report/heart-valve-devices-market

Heart Failure Drugs Market https://www.credenceresearch.com/report/heart-failure-drugs-market

Heart Rate Monitor Market https://www.credenceresearch.com/report/heart-rate-monitor-market

About Us

Credence Research Inc is a global market intelligence and consulting firm founded in 2015. It delivers deep market insights, quantitative analysis, and strategic guidance to business leaders, investors, governments, NGOs, and non-profit groups worldwide. The company helps organizations evaluate markets, understand trends, reduce risk, and make data-driven decisions that support growth and competitive strategy. Credence Research is known for rigorous research methods and comprehensive analytics.

The firm produces detailed reports covering market size, forecasts, growth drivers, trends, and competitive landscapes across many industries. Each report often includes frameworks like PESTLE and Porter's Five Forces to give a complete view of market dynamics and future potential. Credence Research also provides tailored consulting services, due diligence support, go-to-market planning, and pre-IPO research to strengthen client strategies and investment narratives. Its insights come from both primary and secondary research, expert interviews, and advanced data modelling. The firm's client base spans Europe, the Americas, Asia-Pacific, and the Middle East/Africa.

To find out more, visit www.credenceresearch.com or follow us on X.com, LinkedIn and Facebook

Contact Us –

Credence Research Inc,

Tower C-1105, S 25,

Akash Tower,

Vishal Nagar,

Pimple Nilakh, Haveli,

Pune – 411027, India

USA: +1-888-600-6441

Email: sales@credenceresearch.com 

Visit Our Website: https://www.credenceresearch.com/

Logo - https://mma.prnewswire.com/media/2562161/Credence_Research_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/structural-heart-devices-market-to-reach-usd-12-93-billion-by-2032-driven-by-rapid-adoption-of-tavr-and-minimally-invasive-transcatheter-therapies--credence-research-302704384.html

Die vorübergehende Lockerung der US-Sanktionen gegen russisches Erdöl sorgt in der deutschen Politik für deutliche Irritationen. Washington hat entschieden, für 30 Tage den Verkauf von auf See befindlichem russischem Öl zu erlauben, um die Folgen stark gestiegener Energiepreise abzufedern. Aus Berlin kommt quer durch mehrere Parteien Kritik an diesem Schritt, der mitten in den anhaltenden Kampfhandlungen in der Ukraine erfolgt und gleichzeitig mit den US-Luftangriffen auf Ziele im Iran zusammenfällt.

Bundeskanzler Friedrich Merz bezeichnete die Entscheidung der US-Regierung als „falsch“ und machte deutlich, dass Berlin an der bisherigen Sanktionslinie gegen Moskau festhalten will. „Wir halten es für falsch, die Sanktionen zu lockern“, sagte Merz. Bundeswirtschaftsministerin Katharina Reich warnte vor den finanziellen Folgen eines solchen Schrittes: Sie mache sich Sorgen, „dass wir Putins Kriegskassen nicht noch weiter füllen“. Der CDU-Außenpolitiker Roderich Kiesewetter betonte, Russland verdiene durch zusätzliche Öleinnahmen „wieder richtig Geld“ – mit der Folge, dass die Ukraine weiter unter Druck gerate, falls es kein Gegengewicht aus dem Westen gebe.

Besonders scharf fiel die Kritik des Linken-Vorsitzenden Jan van Aken aus, der von einem „doppelt falschen Signal“ sprach. Er verwies darauf, dass US-Präsident Donald Trump selbst einen aus seiner Sicht völkerrechtswidrigen Angriffskrieg führe und den Iran bombardiere, woraufhin die Ölpreise explodierten. Anschließend erlaube Washington den Verkauf russischen Öls: „Dann sagt er im Grunde genommen: Der völkerrechtswidrige Angriffskrieg Russlands ist uns egal. Die dürfen jetzt ihr Öl verkaufen. Was ist denn das für ein Zeichen an die Welt?“ Das signalisiere aus seiner Sicht das „Recht des Stärkeren“ – wer Macht habe, dürfe andere Länder bombardieren.

In der deutschen Debatte formiert sich zugleich Widerspruch gegen den strikten Kurs der Bundesregierung. Das Bündnis Sahra Wagenknecht (BSW) fordert einen nationalen Kurswechsel und drängt darauf, dass Deutschland – anders als bisher – wieder russisches Öl importiert. BSW-Chef Fabio De Masi argumentiert, die USA nutzten russisches Öl zur Dämpfung der Energiepreise, während Deutschland trotz explodierender Kosten darauf verzichte. Er plädiert dafür, über die Raffinerie im brandenburgischen Schwedt erneut russisches Öl zu beziehen, eine Übergewinnsteuer auf Krisenprofiteure einzuführen und die Spritpreise durch eine sofortige Aussetzung der CO₂-Abgabe zu senken.

Damit prallen in Berlin zwei Linien aufeinander: Auf der einen Seite steht der Anspruch, den wirtschaftlichen Druck auf Moskau durch strikte Sanktionen aufrechtzuerhalten, auf der anderen der Wunsch nach Entlastung von Verbrauchern und Industrie in einer Phase hoher Energiepreise. Die US-Sondererlaubnis für russische Ölverkäufe dient dabei sowohl den Kritikern als auch den Befürwortern eines deutschen Kurswechsels als Argument – die einen sehen darin eine gefährliche Aufweichung der Sanktionsfront, die anderen einen Beleg dafür, dass auch enge Verbündete ihre Energiepolitik pragmatisch an den eigenen wirtschaftlichen Interessen ausrichten.